Vir Biotechnology Inc. has announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is an investigational PRO-XTEN® dual-masked T-cell engager targeting prostate-specific membrane antigen (PSMA). This phase of the trial will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5500 in combination therapy for first-line, pre-taxane mCRPC patients. The study builds on encouraging Phase 1 data of VIR-5500 monotherapy in late-line patients, which were presented in January 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251009548229) on October 09, 2025, and is solely responsible for the information contained therein.